Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis

Background: Increased plasma levels of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) have been identified as predictors of cardiac dysfunction and prognosis in congestive heart failure and ischemic heart disease. In severe sepsis patients, however, no information is available...

Full description

Saved in:
Bibliographic Details
Main Authors: Brückmann, Martina (Author) , Huhle, Günter (Author) , Lang, Siegfried (Author) , Haase, Karl Konstantin (Author) , Bertsch, Thomas (Author) , Weiß, Christel (Author) , Kaden, Jens (Author) , Putensen, Christian (Author) , Borggrefe, Martin (Author) , Hoffmann, Ursula (Author)
Format: Article (Journal)
Language:English
Published: July 18, 2005
In: Circulation
Year: 2005, Volume: 112, Issue: 4, Pages: 527-534
ISSN:1524-4539
DOI:10.1161/CIRCULATIONAHA.104.472050
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1161/CIRCULATIONAHA.104.472050
Verlag, lizenzpflichtig, Volltext: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.104.472050
Get full text
Author Notes:Martina Brueckmann, Guenter Huhle, Siegfried Lang, Karl K. Haase, Thomas Bertsch, Christel Weiß, Jens J. Kaden, Christian Putensen, Martin Borggrefe, and Ursula Hoffmann
Description
Summary:Background: Increased plasma levels of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) have been identified as predictors of cardiac dysfunction and prognosis in congestive heart failure and ischemic heart disease. In severe sepsis patients, however, no information is available yet about the prognostic value of natriuretic peptides. Therefore, the aim of the present study was to determine the role of the N-terminal prohormone forms of ANP (NT-proANP) and BNP (NT-proBNP) in the context of outcome of septic patients. Furthermore, the effect of treatment with recombinant human activated protein C [drotrecogin alfa (activated)] on plasma levels of natriuretic peptides in severe sepsis was evaluated. - Methods and Results: Fifty-seven patients with severe sepsis were included. Levels of NT-proANP and NT-proBNP were measured on the second day of sepsis by ELISA. Septic patients with NT-proBNP levels >1400 pmol/L were 3.9 times more likely (relative risk [RR], 3.9; 95% CI, 1.6 to 9.7) to die from sepsis than patients with lower NT-proBNP values (P<0.01). NT-proANP levels, however, were not predictive of survival in our patient population. A highly significant correlation was found between troponin I levels and plasma concentrations of NT-proBNP in septic patients (r=0.68, P<0.0001). In addition, troponin I significantly accounted for the variation in NT-proBNP levels (P<0.0001), suggesting an important role for NT-proBNP in the context of cardiac injury and dysfunction in septic patients. Twenty-three septic patients who received treatment with drotrecogin alfa (activated) presented with significantly lower concentrations of NT-proANP, NT-proBNP, and troponin I compared with patients not receiving drotrecogin alfa (activated). - Conclusions: NT-proBNP may serve as useful laboratory marker to predict survival in patients presenting with severe sepsis.
Item Description:Gesehen am 27.06.2022
Physical Description:Online Resource
ISSN:1524-4539
DOI:10.1161/CIRCULATIONAHA.104.472050